Stereotaxis to Acquire Robocath for $20M Upfront, Expanding Endovascular Robotics Footprint
Event summary
- Stereotaxis to acquire Robocath for $20M upfront, with up to $25M in milestone-based payments.
- Robocath’s R-One+ system is the only commercially available robotic solution for percutaneous coronary interventions in Europe.
- Combined platform will integrate Stereotaxis’ magnetic navigation with Robocath’s mechanical robotic system.
- Transaction expected to close mid-2026, with breakeven projected by year three post-acquisition.
- Robocath will operate as a wholly owned subsidiary of Stereotaxis.
The big picture
Stereotaxis’ acquisition of Robocath solidifies its position as a leader in endovascular robotics, combining complementary technologies to create a fully-integrated robotic solution. This move comes as the interventional cardiology and neurointerventions markets continue to grow, driven by demand for minimally invasive procedures. The deal underscores the strategic importance of robotic precision in expanding access to advanced cardiovascular therapies.
What we're watching
- Integration Challenges
- How Stereotaxis will merge Robocath’s mechanical robotic system with its own magnetic navigation technology.
- Regulatory Timelines
- The pace at which Stereotaxis can secure FDA clearance for Robocath’s next-generation system.
- Revenue Growth
- Whether the combined platform can accelerate Stereotaxis’ entry into the $10B+ interventional cardiology and neurointerventions markets.
Related topics